What's behind Abbott Laboratories' latest 2.4% stock pullback?

Traders Union
All News
Financial News
Abbott laboratories slips 2.44% today

Highlights

Abbott Laboratories is projected to report Q2 2026 earnings of $1.28 per share on $12.52 billion in revenue, with diagnostics, devices, and pharmaceuticals driving growth.
The company declared a quarterly dividend of $0.63 per share payable August 17, 2026, despite ongoing stock price pressure and expected weakness in nutrition.
Shares trade below key moving averages, momentum signals remain mixed, and the stock is likely to consolidate between $86.27 and $92.13 with a 70% probability of downside.

Earnings optimism in key segments meets persistent share price pressure

Abbott Laboratories is scheduled to release its second quarter 2026 earnings on July 16, 2026, with Wall Street expecting earnings of $1.28 per share and revenue of $12.52 billion. The company also announced a quarterly dividend of $0.63 per share for shareholders of record as of July 15, 2026, to be paid on August 17, 2026. Earnings growth is anticipated in Diagnostics, Devices, and Established Pharmaceuticals, while Nutrition is expected to show weaker performance. These developments were accompanied by continued pressure on the stock price.

Anton Kharitonov, expert at Traders Union, notes sustained selling pressure in Abbott Laboratories with the price sitting beneath its 20-day and 200-day moving averages. He observes a bearish technical alignment and highlights weak momentum despite some neutral-to-bullish signals. The latest dividend announcement and anticipation of Q2 earnings have failed to lift market sentiment. Kharitonov believes the downside risk prevails, especially with Nutrition expected to lag other segments. "The technical structure and muted investor response to company updates point to limited upside in the near term," he warns.

Viktoras Karapetjanc, expert at Traders Union, sees opportunity in Abbott's upcoming Q2 results and expanding Diagnostics and Devices segments. He underscores Wall Street's solid expectations for both earnings and revenue, pointing to a company with lasting growth drivers. The confirmed dividend payout and ongoing product momentum support positive investor sentiment. Karapetjanc maintains confidence in a potential upside move if key resistance is broken. "With strong underlying trends and sector growth, bullish structure remains intact for Abbott despite short-term volatility," he asserts.

Mixed momentum as price tests technical resistance in bearish trend

Abbott Laboratories is trading below its 20-day moving average at $91.92 and its 200-day moving average at $110.61, but remains above the 50-day moving average at $89.19. This setup suggests ongoing short- and long-term selling pressure, with the MA-50 vs MA-200 alignment pointing to a bearish longer-term trend. Immediate resistance is at $90.45 and near-term support is at $89.19. Momentum indicators present a mixed picture: the MACD shows a 'Strong Buy' outlook, the ADX is neutral, and the RSI is neutral-to-bullish with a 'Buy' forecast. The Stochastic RSI reads 0, flagging an oversold condition, while the CCI and Awesome Oscillator are neutral. Bull/Bear Power is positive at 0.88, highlighting buyer control intraday but with an overbought forecast, which may indicate exhaustion. The stock fell to $89.86 after a downside gap, currently trading near the intraday high with initial pressure stabilizing near session highs. Uncertain direction is suggested by conflicting momentum and oscillator signals.

Earlier, analysts noted that Abbott Laboratories was facing persistent bearish momentum as sellers maintained control and technical indicators favored a cautious outlook. The current setup reinforces this view, with ongoing downside risks underscored by upcoming earnings and a key support level at $89.19 that traders should monitor for potential further weakness.

Source of Data: ABT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.